Sex Hormones and Gender Differences
Sex hormones and gender differences represent one of the most striking yet inadequately explained features of ME/CFS epidemiology and pathophysiology. The consistent 3–4:1 female-to-male prevalence ratio, menstrual cycle exacerbations reported by female patients, early menopause associations, and sex-specific patterns of immune dysfunction and steroid hormone abnormalities collectively indicate that reproductive hormones play central roles in disease susceptibility, expression, and progression.
1 Epidemiology of Sex Differences
A systematic review and meta-analysis by Lim et al. (2020) synthesized prevalence data from 45 articles representing 46 studies and 56 prevalence datasets spanning 1980–2018 (Lim et al. 2020). The analysis documented overall ME/CFS prevalence of 0.89% using CDC-1994 criteria, with female prevalence approximately 1.5–2.0 fold higher than males across all studies. In the total population, prevalence was 2.24% ± 2.59% in females versus 1.11% ± 1.05% in males. General population studies showed 2.83% versus 1.39%, and meta-analysis pooled estimates indicated 1.36% versus 0.89%. The female-to-male ratio consistently ranges from 3:1 to 4:1 across geographic regions, diagnostic criteria, and study methodologies.
More recent estimates using large-scale medical claims data and machine learning by Jason et al. (2018) confirmed the persistent female predominance, though highlighting that 35–40% of ME/CFS patients are male—a substantial population whose experiences may differ from the predominantly studied female cohorts (Jason and Mirin 2018). The consistency of the sex ratio across diverse populations and diagnostic approaches argues strongly for biological sex differences in disease susceptibility or expression rather than artifacts of health-seeking behavior or diagnostic bias.
2 Sex-Specific Pathophysiology: NIH Deep Phenotyping Findings
The 2024 NIH deep phenotyping study by Walitt et al. employed multi-omics analysis to directly compare male and female ME/CFS patients (Walitt et al. 2024). This rigorous investigation revealed fundamentally different pathophysiological signatures. Males showed altered T cell activation patterns and abnormal innate immunity markers, while females demonstrated abnormal B cell function and altered white blood cell growth patterns. The sexes exhibited distinct inflammatory marker profiles, divergent gene expression patterns in immune cells, different immune cell population distributions, and sex-specific metabolic marker abnormalities.
This finding challenges the implicit assumption in ME/CFS research that male and female patients share a common pathophysiology differing only in prevalence. Instead, it suggests that ME/CFS may represent partially distinct disease processes in males and females requiring sex-stratified approaches to diagnosis, biomarker development, and treatment.
Complementing the NIH findings, Shahbaz et al. (2025) documented sex-specific immune dysregulation in long COVID patients with ME/CFS (Shahbaz et al. 2025). Females exhibited decreased lymphocyte counts with increased neutrophils and monocytes (a myelopoiesis shift), elevated pro-inflammatory cytokines, and upregulated type 2 interferon signaling (IP-10, IFN-\(\gamma\)). Males showed fewer inflammatory alterations overall, with more balanced profiles, elevated anti-inflammatory IL-10, and IL-1 signaling dominance rather than interferon predominance. These immune differences likely reflect underlying hormonal influences on immune cell development, activation, and cytokine production.
3 Steroid Hormone Abnormalities
Pipper et al. (2024) conducted the first comprehensive sex-stratified analysis of steroid hormones in ME/CFS using high-precision UHPLC-MS/MS (ultra-high performance liquid chromatography tandem mass spectrometry) (Pipper et al. 2024). This study of 97 total participants revealed striking sex-specific and severity-dependent patterns. Female patients with severe ME/CFS demonstrated elevated 11-deoxycortisol (a cortisol precursor) and 17\(\alpha\)-hydroxyprogesterone, suggesting impaired final enzymatic steps in cortisol biosynthesis. Females with mild-to-moderate disease showed increased progesterone levels. Male patients with mild-to-moderate ME/CFS exhibited frankly reduced cortisol and corticosterone but paradoxically elevated progesterone—an unexpected finding suggesting complex dysregulation of steroidogenic pathways.
The machine learning classifier achieved 71.2% accuracy for discriminating female ME/CFS patients from controls and 84.6% accuracy for males based solely on steroid hormone profiles, supporting the potential development of sex-specific hormonal biomarkers for diagnosis and disease monitoring.
Single study (Pipper 2024, n=97 total). This is the first sex-stratified steroid hormone analysis in ME/CFS using UHPLC-MS/MS. Subgroup sizes are small (particularly male severe ME/CFS). The machine learning classifier was not validated on an independent test set. Independent replication with larger, sex-balanced cohorts is required.
These findings indicate that sex hormone abnormalities in ME/CFS extend beyond simple deficiency or excess of individual hormones to involve coordinated dysregulation of steroidogenic pathways, enzyme activities, and metabolic ratios. The sex-specific patterns suggest that estrogen and progesterone in females versus testosterone and its metabolites in males exert distinct effects on disease expression.
4 Reproductive Health and Gynecological Risk Factors
4.1 Menstrual Cycle Effects and Hormonal Fluctuations
The majority of premenopausal women with ME/CFS report significant symptom exacerbations related to menstrual cycle phases, particularly during the premenstrual week (late luteal phase when progesterone declines rapidly) and during menstruation itself. Common cyclical exacerbations include increased fatigue and post-exertional malaise severity, worsened cognitive impairment and brain fog, intensified pain and sensory sensitivity, heightened orthostatic intolerance symptoms, and mood disturbances such as irritability, anxiety, and depression.
Preliminary findings from chronobiology-based studies mapping hormonal fluctuations across the menstrual cycle in ME/CFS reveal systematic symptom-hormone relationships. Fatigue and pain peak premenstrually when estradiol and progesterone levels fall. Cognitive impairment shows lowest severity at ovulation when estradiol peaks. Low estradiol and progesterone concentrations correlate with higher fatigue and pain ratings. Additionally, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels positively correlate with fatigue severity and orthostatic symptoms, suggesting pituitary dysregulation may contribute to symptom variability. These patterns suggest that the absolute levels of sex hormones may be less important than the dynamic fluctuations and ratios between estrogen, progesterone, and pituitary gonadotropins. The rapid hormonal changes during certain cycle phases may destabilize physiological systems already compromised by ME/CFS, triggering symptom exacerbations.
4.2 Gynecological Comorbidities and Early Menopause
Population-based case-control studies by Boneva et al. have identified specific gynecological risk factors associated with ME/CFS development (Boneva, Lin, and Unger 2011) (Boneva et al. 2015). The 2011 study documented that ME/CFS cases reported significantly higher rates of pelvic pain unrelated to menstruation (22.2% versus 1.7% in controls), endometriosis diagnosis (36.1% versus 16.7%), prolonged periods of amenorrhea (absence of menstruation), and history of gynecological surgery including hysterectomy and oophorectomy. Premenopausal women with ME/CFS tended toward lower luteal phase progesterone with higher FSH.
Most strikingly, the 2015 study revealed that women with ME/CFS experienced menopause approximately 11 years earlier than controls (mean age 37.6 years versus 48.6 years) (Boneva et al. 2015). Early menopause (<40 years) represents premature ovarian insufficiency, indicating fundamental dysfunction of the hypothalamic-pituitary-gonadal (HPG) axis. This finding suggests that HPG dysfunction may precede or contribute to ME/CFS development rather than merely resulting from the disease.
Both studies (Boneva 2011, 2015) derive from the same CDC research group using the same Georgia cohort. While internally consistent, independent replication of the early menopause finding and gynecological risk factors in non-CDC populations is needed.
The mechanisms connecting gynecological abnormalities to ME/CFS remain incompletely understood but likely involve bidirectional interactions. Chronic inflammation (documented in Chapter Immune System Dysfunction) affects ovarian function, endometrial health, and hormonal regulation. Conversely, sex hormone abnormalities modulate immune function, with estrogen generally enhancing immune responses (potentially contributing to female predominance of autoimmune diseases) and progesterone providing immunosuppressive and anti-inflammatory effects. Disruption of these hormonal immunomodulatory signals could perpetuate the immune dysfunction characteristic of ME/CFS.
5 Testosterone and Androgens
While research has focused predominantly on female ME/CFS patients due to the higher prevalence, emerging evidence indicates that male patients exhibit distinct hormonal abnormalities, particularly involving androgens (testosterone, DHEA, and their metabolites). A pilot study of 23 women ages 35–55 with ME/CFS found that 89% had suboptimal DHEA-S (dehydroepiandrosterone sulfate) levels. Supplementation with DHEA led to statistically significant improvements: 18% reduction in pain, 21% reduction in fatigue, 35% reduction in anxiety, 26% improvement in thinking ability, 17% improvement in memory, and 22% improvement in sexual function.
Falsifiability: weakly — Falsified if DHEA-S and testosterone levels are comparable to healthy controls, or if androgen replacement fails to improve fatigue and cognition in patients with documented deficiency
Androgens, particularly DHEA and testosterone, serve multiple physiological functions beyond reproductive roles. They support mitochondrial function and cellular energy production, promote muscle mass maintenance and physical strength, modulate immune responses with generally anti-inflammatory effects, influence mood, motivation, and cognitive function, and affect pain perception and nociceptive processing. Deficiency of these hormones could mechanistically contribute to core ME/CFS symptoms including fatigue, cognitive impairment, reduced physical capacity, and pain amplification.
The sex-specific steroid profiles identified by Pipper et al. showing reduced cortisol but elevated progesterone in male ME/CFS patients suggest complex interactions between the HPA axis and gonadal steroid production (Pipper et al. 2024). Further research specifically examining male ME/CFS patients is critically needed to elucidate androgen metabolism and its therapeutic potential.
6 Mechanisms of Sex Hormone Influence on ME/CFS
Sex hormones exert pervasive effects on immune function, energy metabolism, neurotransmitter systems, and autonomic regulation—all domains disrupted in ME/CFS. Understanding these mechanisms illuminates how hormonal dysregulation contributes to pathophysiology.
6.1 Immune Modulation by Sex Hormones
Estrogen generally enhances immune responses. It promotes B cell maturation and antibody production, enhances T helper 2 (Th2) responses, increases pro-inflammatory cytokine production in certain contexts, and potentially contributes to higher autoimmune disease prevalence in females. Progesterone exerts immunosuppressive effects. It promotes T regulatory cell (Treg) function essential for immune tolerance, suppresses Th1 inflammatory responses, reduces pro-inflammatory cytokine production, and normally balances estrogen’s immune-enhancing effects during the menstrual cycle.
Testosterone generally suppresses immune activation. It reduces B cell activity and antibody production, suppresses pro-inflammatory cytokine secretion, and potentially explains lower autoimmune disease rates in males. The loss of normal hormonal modulation of immune function—whether through estrogen-progesterone imbalance in females, DHEA/testosterone deficiency in both sexes, or altered receptor sensitivity—could permit the chronic immune activation documented in Chapter Immune System Dysfunction to persist unchecked.
6.2 Neuroendocrine Integration
The sex-specific pathophysiology documented by Walitt et al. and Shahbaz et al. likely reflects coordinated neuroendocrine-immune interactions rather than isolated hormonal effects (Walitt et al. 2024) (Shahbaz et al. 2025). The hypothalamus and pituitary integrate signals from immune cytokines, metabolic hormones, and gonadal steroids to coordinate systemic responses. In ME/CFS, this integration appears fundamentally disrupted, with females showing stronger interferon signatures (potentially reflecting estrogen’s enhancement of interferon responses) and males showing more balanced but still abnormal patterns (potentially reflecting testosterone’s dampening effects on certain immune pathways).
The early menopause and gynecological abnormalities documented by Boneva et al. suggest that the HPG axis dysfunction may represent a form of neuroendocrine exhaustion analogous to the HPA axis hypofunction discussed earlier in this chapter (Boneva et al. 2015). Chronic immune activation and cytokine exposure may dysregulate both axes, creating a state of multi-system endocrine insufficiency despite the absence of structural gland failure.
The sex-specific endocrine and immune patterns reported across studies have important epistemic boundaries:
- The Pipper et al. steroid analysis (n=97 total) has not been replicated, and subgroup sizes (particularly male severe ME/CFS) are too small for robust conclusions. The machine learning classifier lacked independent validation.
- The Boneva early menopause finding (mean 37.6 vs. 48.6 years) derives from a single CDC cohort; selection bias, recall bias, and confounders (medications, comorbidities) have not been excluded by independent replication.
- Hormonal differences between male and female ME/CFS patients do not establish that sex hormones cause the differing immune signatures—shared genetic susceptibility, sex-chromosome immune gene dosage, or other confounders may explain both.
- The inference that “ME/CFS may represent partially distinct disease processes in males and females” is a hypothesis generated from cross-sectional data, not a demonstrated conclusion.
A further hormonal-immune mechanism with direct relevance to the female predominance of the MCAS/POTS/hEDS cluster is the direct modulation of mast cells by estradiol and progesterone — estradiol priming mast cells toward activation, progesterone modulating (often suppressing) them. This axis is developed in the reproductive-lifespan chapter (see Estradiol and Progesterone Directly Modulate Mast Cell Activation), which also treats its implications for hormone replacement therapy.